ClinicalTrials.gg
CompletedNCT00568178Updated May 23, 2024Results posted

An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))

A Phase 3 interventional study of Losartan Potassium and Comparator: Placebo (Losartan) in Proteinuria, sponsored by Organon and Co. Completed. Open to participants aged 12 Months to 17 Years. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jun 2007, registered Dec 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
12 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing losartan in Proteinuria — 1 open to participants now, 1 under way, none of them phase 3. Losartan · Proteinuria.

Enrollment
4th of 14
306 · median 164
Started
2007
the only one that year
Phase 3
5 of 15
none open now
Registered
8th of 15
by date
Lead sponsor
1 of 15
Organon and Co

Among the 15 studies testing losartan in Proteinuria, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2007, is one of 5 in phase 3, and was the 8th registered.

Proteinuria

329 studies on the registry are indexed under Proteinuria; 44 are open to participants now.

Browse Proteinuria studies →

Open to participants now

1 of the 15 studies testing losartan in Proteinuria is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 32 Proteinuria studies recruiting now, 12 (38%) set no upper age limit and 16 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 12 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing losartan in Proteinuria, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of losartan on proteinuria in pediatric patients.

Read the detailed description

The study included a 12-week double-blind treatment phase and a 36-month open-label extension phase. Participants who completed or discontinued the initial 12-week phase of the study and who opted to participate in the open label extension phase were randomized to either losartan or enalapril at a dose of the investigator's choosing for the duration of the extension. The open label extension was designed to continue until the 100th participant completed 3 years of follow-up.

03

Conditions studied

  • Proteinuria

Browse trials for

04

Who can participate

Ages eligible
12 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is 1 to 17 years of age
  • Able to provide a first-morning urine sample each day during the study
  • Documented history of proteinuria associated with chronic kidney disease of any origin
  • Signed consent of parent and/or legal guardian

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or nursing
  • Requires more than 2 medications to control high blood pressure
  • Has undergone major organ transplantation (e.g. heart, kidney, liver)
  • Known sensitivity to losartan or other similar drugs, or any history of angioneurotic edema
  • Known sensitivity to amlodipine or other calcium channel blocker
  • Requires cyclosporine to treat renal disease (kidney disease)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
306 participants (actual)

Study arms

  • Experimental
    Losartan Double-Blind Base Study (12-weeks)

    Normotensive participants received losartan. Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo).

    Drug: Losartan Potassium · Other: Comparator: Placebo (Losartan)

  • Active comparator
    Amlodipine Double-Blind Base Study (12-weeks)

    Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.

    Other: Comparator: Placebo (Losartan) · Drug: Comparator: amlodipine besylate · Other: Comparator: Placebo (amlodipine besylate) · Other: Placebo (Losartan)

  • Experimental
    Losartan Open-Label Extension Phase (Month 36)

    Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).

    Drug: Losartan Potassium

  • Active comparator
    Enalapril Open-Label Extension Phase (Month 36)

    Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).

    Drug: Enalapril Maleate

Interventions

  • Losartan Use During the Double-Blind Treatment Phase: Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed \<50 kg) or 100 mg/day (if the patient weighed ≥50 kg). Losartan Use During the Treatment Extension Phase: Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance.

    Also known as: Cozaar®

  • OtherComparator: Placebo (Losartan)

    Placebo (losartan suspension), administered orally, once daily for 12 weeks

  • Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks

    Also known as: NORVASC®

  • OtherComparator: Placebo (amlodipine besylate)

    Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks

    Also known as: NORVASC®

  • OtherPlacebo (Losartan)

    Normotensive patients randomized to losartan placebo for 12 weeks.

  • Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.

    Also known as: Vasotec®, Renitec®

06

What researchers measure

Primary outcomes

  1. Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12

    Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline\*, after approximately twelve weeks of treatment. Baseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period.

    Time frame: Baseline and Week 12

  2. Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36

    Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline\*, after approximately three years of treatment. \*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase.

    Time frame: Baseline and Month 36

  3. Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36

    The outcome measure of glomerular filtration rate was based on mL/min/1.73m\^2, as determined by the Schwartz formula: GFR = _____0.55 x height (cm)_______ divided by serum creatinine (mg/dL) GFR values were compared to the baseline GFR measure. \[Note: For male participants, ages 13 to 17 years, 0.70 was used as the multiplier in place of 0.55\] Baseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase.

    Time frame: Baseline and Month 36

Secondary outcomes

  1. Double-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12

    Time frame: Baseline and Week 12

  2. Double-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12

    Time frame: Baseline and Week 12

07

Results

Posted Oct 30, 2009

Participant flow

As of March 2011, the study was completed. Phase III First Patient In: 21Jun07; Last Patient Last Visit (double-blind base study): 16Sep08; and (open-label extension): 31Mar11. The study included 52 centers (USA, Europe, Latin America, and Asia) and participants included children aged 6-17 (hypertensive) or 1-17 (normotensive) with proteinuria.

Double Blind Base Study
Participant flow — Double Blind Base Study
MilestoneLosartan Double Blind NormortensivePlacebo Double Blind NormotensiveLosartan Double Blind HypertensiveAmlodipine Double Blind HypertensiveLosartan Open Label ExtensionEnalapril Open Label Extension
Started122124303000
Completed116118292500
Not completed661500
Withdrew: Adverse event021200
Withdrew: Lost to follow-up100100
Withdrew: Physician decision110100
Withdrew: Protocol violation320000
Withdrew: Withdrawal by subject110000
Withdrew: Progressive disease000100
Open Label Extension
Participant flow — Open Label Extension
MilestoneLosartan Double Blind NormortensivePlacebo Double Blind NormotensiveLosartan Double Blind HypertensiveAmlodipine Double Blind HypertensiveLosartan Open Label ExtensionEnalapril Open Label Extension
Started0000134134
Completed00005554
Not completed00007980
Withdrew: Adverse event0000118
Withdrew: Protocol violation000010
Withdrew: Lost to follow-up0000611
Withdrew: Physician decision000098
Withdrew: Pregnancy000001
Withdrew: Progressive disease000031
Withdrew: Termination of trial00004547
Withdrew: Withdrawal by subject000044

Outcome measures

PrimaryDouble-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12

Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline\*, after approximately twelve weeks of treatment. Baseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period.

Time frame:
Baseline and Week 12
Reported as:
Geometric mean · Percent Change in Pr/Cr
Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12
Percent Change in Pr/CrLosartanAmlodipine/Placebo
Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12-35.80 (-43.11 to -27.55)1.37 (-10.27 to 14.51)
Statistical analysis
  • Losartan vs Amlodipine/Placebo · Mixed Models Analysis · p = 0.001 · Ratio in geometric mean: 0.63 · 95% CI 0.54 to 0.74
SecondaryDouble-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mm Hg
Double-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12
mm HgLosartan-Hypertensive ParticipantsAmlodipine-Hypertensive Participants
Double-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12-5.5 (-8.6 to -2.4)-0.1 (-3.3 to 3.1)
Statistical analysis
  • Losartan-Hypertensive Participants vs Amlodipine-Hypertensive Participants · Mixed Models Analysis · Mean difference (final values): -5.4 · 95% CI -9.9 to -1.0
SecondaryDouble-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mm Hg
Double-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12
mm HgLosartan-Hypertensive ParticipantsAmlodipine-Hypertensive Participants
Double-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12-3.8 (-7.0 to -0.7)0.8 (-2.5 to 4.1)
Statistical analysis
  • Losartan-Hypertensive Participants vs Amlodipine-Hypertensive Participants · Mixed Models Analysis · Mean difference (final values): -4.6 · 95% CI -9.2 to -0.1
PrimaryOpen Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36

Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline\*, after approximately three years of treatment. \*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase.

Time frame:
Baseline and Month 36
Reported as:
Geometric mean · Percent Change in Pr/Cr
Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36
Percent Change in Pr/CrLosartan Open Label ExtensionEnalapril Open Label Extension
Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36-30.01 ± 5.02-40.45 ± 2.10
Statistical analysis
  • Losartan Open Label Extension vs Enalapril Open Label Extension · Mixed Models Analysis · Geometric mean ratio: 1.18 · 95% CI 0.86 to 1.60An unstructured variance-covariance was used.
PrimaryOpen Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36

The outcome measure of glomerular filtration rate was based on mL/min/1.73m\^2, as determined by the Schwartz formula: GFR = _____0.55 x height (cm)_______ divided by serum creatinine (mg/dL) GFR values were compared to the baseline GFR measure. \[Note: For male participants, ages 13 to 17 years, 0.70 was used as the multiplier in place of 0.55\] Baseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase.

Time frame:
Baseline and Month 36
Reported as:
Least squares mean · Change in GFR mL/min1.73m^2
Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36
Change in GFR mL/min1.73m^2Losartan Open Label ExtensionEnalapril Open Label Extension
Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 363.3 ± 66.37.0 ± 53.2
Statistical analysis
  • Losartan Open Label Extension vs Enalapril Open Label Extension · Mixed Models Analysis · Least square mean: -3.8 · 95% CI -15.2 to 7.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Losartan: Double-Blind Base Study—8/152 (5.3%)71/152 (46.7%)
Amlodipine/Placebo: Double-Blind Base Study—5/154 (3.2%)66/154 (42.9%)
Losartan Open-Label Extension—27/134 (20.1%)83/134 (61.9%)
Enalapril: Open-Label Extension—25/134 (18.7%)78/134 (58.2%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventLosartan: Double-Blind Base StudyAmlodipine/Placebo: Double-Blind Base StudyLosartan Open-Label ExtensionEnalapril: Open-Label Extension
PneumoniaInfections and infestations0/1520/1542/1343/134
PyelonephritisInfections and infestations0/1520/1543/1340/134
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/1520/1541/1343/134
Renal failure acuteRenal and urinary disorders0/1520/1543/1342/134
LeukopeniaBlood and lymphatic system disorders0/1520/1542/1340/134
DiarrhoeaGastrointestinal disorders0/1520/1540/1342/134
Urinary tract infectionInfections and infestations0/1522/1542/1341/134
ConvulsionNervous system disorders0/1520/1541/1342/134
HaematuriaRenal and urinary disorders0/1520/1542/1341/134
Renal impairmentRenal and urinary disorders0/1520/1542/1341/134
Most frequent other events
Showing 10 of 18
Most frequent other events
EventLosartan: Double-Blind Base StudyAmlodipine/Placebo: Double-Blind Base StudyLosartan Open-Label ExtensionEnalapril: Open-Label Extension
NasopharyngitisInfections and infestations24/15219/15431/13420/134
PharyngitisInfections and infestations6/1526/15421/13420/134
HeadacheNervous system disorders13/15220/1547/13412/134
VomitingGastrointestinal disorders6/1524/15416/1344/134
Upper respiratory tract infectionInfections and infestations7/1529/15415/1349/134
DiarrhoeaGastrointestinal disorders8/1527/15412/1347/134
AnaemiaBlood and lymphatic system disorders0/1520/15411/1348/134
CoughRespiratory, thoracic and mediastinal disorders5/1526/1548/13411/134
Urinary tract infectionInfections and infestations2/1523/15410/13410/134
BronchitisInfections and infestations9/1528/1549/1349/134

Baseline characteristics

Age, Continuous
Age, Continuous(years)LosartanAmlodipine/PlaceboTotal
Mean10.4 ± 4.79.7 ± 4.610.1 ± 4.7
Age, Customized
Age, Customized(participants)LosartanAmlodipine/PlaceboTotal
≤6 Years of Age334275
7-12 Years of Age5757114
13-17 Years of Age6255117
Sex: Female, Male
Sex: Female, Male(Participants)LosartanAmlodipine/PlaceboTotal
Female6664130
Male8690176
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LosartanAmlodipine/PlaceboTotal
Hispanic or Latino7982161
Not Hispanic or Latino7372145
Unknown or Not Reported000
Hypertensive
Hypertensive(Participants)LosartanAmlodipine/PlaceboTotal
Yes303060
No122124246
Prior Angiotensin Converting Enzyme Inhibitor /Angiotensin II Type I Receptor Blocker (ACE-I/ARB)Use
Prior Angiotensin Converting Enzyme Inhibitor /Angiotensin II Type I Receptor Blocker (ACE-I/ARB)Use(Participants)LosartanAmlodipine/PlaceboTotal
Yes8381164
No6973142
Race
Race(participants)LosartanAmlodipine/PlaceboTotal
Asian262652
Black5510
Multi-Racial363470
White7785162
Other8412
Region
Region(Participants)LosartanAmlodipine/PlaceboTotal
United States151025
Outside of United States137144281

8 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, Lam C. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome. Pediatr Nephrol. 2013 May;28(5):737-43. doi: 10.1007/s00467-012-2372-9. Epub 2012 Dec 4. PubMed 23207876 ↗
  • Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C. Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int. 2012 Oct;82(7):819-26. doi: 10.1038/ki.2012.210. Epub 2012 Jun 27. PubMed 22739977 ↗
  • Webb NJ, Lam C, Shahinfar S, Strehlau J, Wells TG, Gleim GW, Le Bailly De Tilleghem C. Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant. 2011 Aug;26(8):2521-6. doi: 10.1093/ndt/gfq797. Epub 2011 Feb 1. PubMed 21285125 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2007 to primary completion in Sep 2008, 15 months.

Results were first posted in Oct 2009, 1 year 1 month after primary completion.

Of 20 phase 3 interventional studies under Proteinuria, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 78. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2007
First posted
Dec 5, 2007
StartActual
Jun 1, 2007
Primary completionActual
Sep 1, 2008
CompletionActual
Mar 1, 2011
Results first posted
Oct 30, 2009
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00568178
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Dec 5, 2007
Start date
Jun 1, 2007
Primary completion
Sep 1, 2008
Completion
Mar 1, 2011
Results posted
Oct 30, 2009
Last update
May 23, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion